Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | STAT1 | P42224 | 1/20 | 0.52 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.52 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | UBE2N | P61088 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159535 | 1.00 | GRM4 (0.59) | GRM4ALDH1A1LMNAMAPTKDM4E | |
| Acetic Acid SCHEMBL28264875 | 0.97 | GRM4 (0.57) | GRM4ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL3997305 | 0.86 | LMNA (0.66) | ALDH1A1LMNAMAPTKDM4ESAE1 | |
| SCHEMBL30355120 | 0.86 | LMNA (0.66) | ALDH1A1LMNAMAPTKDM4ESAE1 | |
| SCHEMBL15972268 | 0.86 | GRM4 (0.59) | GRM4ALDH1A1LMNAMAPTSTAT1 | |
| SCHEMBL19661750 | 0.85 | GRM4 (0.58) | GRM4ALDH1A1LMNAMAPTSTAT1 | |
| SCHEMBL16896837 | 0.84 | GRM4 (0.54) | GRM4ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL22658883 | 0.84 | GRM4 (0.54) | GRM4ALDH1A1LMNAMAPTSTAT1 | |
| SCHEMBL29407648 | 0.84 | GRM4 (0.54) | GRM4ALDH1A1LMNAMAPTSTAT1 | |
| SCHEMBL30492996 | 0.84 | SMN1; SMN2 (0.68) | ALDH1A1LMNAMAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111205281-B | Heterocyclic compounds and their use | 阮富强 | 2022-12-27 | — | — | CN | disclosed |
| CN-111205281-A | Heterocyclic compounds and their use | 阮富强 | 2020-05-29 | — | — | CN | disclosed |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2020-03-17 | — | — | US | disclosed |
| US-10442799-B1 | Heterocyclic compounds and uses thereof | RUAN FUQIANG (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190308963-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | RUAN FUQIANG (US) | 2019-10-10 | — | — | US | disclosed |
| US-20180339982-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-11-29 | — | — | US | disclosed |
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-11-01 | — | — | US | disclosed |
| US-10077259-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2018-09-18 | — | — | US | disclosed |
| EP-3092227-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-07-11 | — | — | EP | disclosed |
| EP-3092227-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-07-11 | — | — | EP | disclosed |
| WO-2008101938-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZONITRILE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101938-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZONITRILE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008055870-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZONITRILE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055870-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZONITRILE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1606268-A1 | HETEROCYCLIC KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
| CN-1058262-C | Novel 1-phenylalkanone 5-HT4Receptor ligands | SYNTEX INC (US) | 2000-11-08 | — | — | CN | disclosed |
| CN-1124485-A | Novel 1-phenylalkanone 5-HT4Receptor ligands | SYNTEX A INC (US) | 1996-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308963-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRD4, BICRA, BET1 | GRM4 2953/4885ALDH1A1 4202/4885LMNA 2247/4885 |
| US-10442799-B1 | Heterocyclic compounds and uses thereof | BRD4, BICRA, BET1 | GRM4 2953/4885ALDH1A1 4202/4885LMNA 2247/4885 |
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD4, BRD2 | GRM4 4721/4885ALDH1A1 1254/4885LMNA 1428/4885 |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | GRM4 4052/4885ALDH1A1 2391/4885LMNA 2735/4885 |
| US-20180339982-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | GRM4 4748/4885ALDH1A1 2949/4885LMNA 823/4885 |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | GRM4 4748/4885ALDH1A1 2949/4885LMNA 823/4885 |
| US-10077259-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | GRM4 4748/4885ALDH1A1 2949/4885LMNA 823/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | GRM4 4043/4885ALDH1A1 3257/4885LMNA 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.